CA1314211C - Agent for reducing nephrotoxicity caused by cyclosporin administration - Google Patents
Agent for reducing nephrotoxicity caused by cyclosporin administrationInfo
- Publication number
- CA1314211C CA1314211C CA000580729A CA580729A CA1314211C CA 1314211 C CA1314211 C CA 1314211C CA 000580729 A CA000580729 A CA 000580729A CA 580729 A CA580729 A CA 580729A CA 1314211 C CA1314211 C CA 1314211C
- Authority
- CA
- Canada
- Prior art keywords
- group
- ciclosporin
- agent
- administration
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 36
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 36
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 36
- 206010029155 Nephropathy toxic Diseases 0.000 title claims abstract description 22
- 231100000417 nephrotoxicity Toxicity 0.000 title claims abstract description 20
- 230000007694 nephrotoxicity Effects 0.000 title claims abstract description 19
- 229930105110 Cyclosporin A Natural products 0.000 title 1
- 229930182912 cyclosporin Natural products 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- -1 organogermanium compound Chemical class 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
- 229910052751 metal Inorganic materials 0.000 claims abstract description 8
- 239000002184 metal Substances 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 125000003277 amino group Chemical group 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 4
- 239000011591 potassium Substances 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 102000016943 Muramidase Human genes 0.000 claims abstract description 3
- 108010014251 Muramidase Proteins 0.000 claims abstract description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 3
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 3
- 239000004325 lysozyme Substances 0.000 claims abstract description 3
- 229960000274 lysozyme Drugs 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 11
- 229940109239 creatinine Drugs 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000000306 component Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910052732 germanium Inorganic materials 0.000 description 4
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical group [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 125000000082 organogermanium group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000007665 chronic toxicity Effects 0.000 description 3
- 231100000160 chronic toxicity Toxicity 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 235000008085 high protein diet Nutrition 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- XRYJTKGEJGVBCC-UHFFFAOYSA-N 2-germylpropanoic acid Chemical compound CC([GeH3])C(O)=O XRYJTKGEJGVBCC-UHFFFAOYSA-N 0.000 description 1
- ZJUHNMADISSFJZ-UHFFFAOYSA-N 2-trichlorogermylpropanoic acid Chemical compound OC(=O)C(C)[Ge](Cl)(Cl)Cl ZJUHNMADISSFJZ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009588 inulin clearance Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/30—Germanium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62273746A JP2698870B2 (ja) | 1987-10-29 | 1987-10-29 | シクロスポリンの投与による腎毒性の軽減剤 |
| JP273746/1987 | 1987-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1314211C true CA1314211C (en) | 1993-03-09 |
Family
ID=17531994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000580729A Expired - Lifetime CA1314211C (en) | 1987-10-29 | 1988-10-20 | Agent for reducing nephrotoxicity caused by cyclosporin administration |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4919917A (enExample) |
| JP (1) | JP2698870B2 (enExample) |
| CA (1) | CA1314211C (enExample) |
| DE (1) | DE3836652A1 (enExample) |
| FR (1) | FR2622446B1 (enExample) |
| GB (1) | GB2211410B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01149723A (ja) * | 1987-12-07 | 1989-06-12 | Asai Gerumaniumu Kenkyusho:Kk | 骨芽細胞活性化剤 |
| AU635045B2 (en) * | 1989-07-20 | 1993-03-11 | Asai Germanium Research Institute Co., Ltd | Agent for preventing and treating opacity of lens |
| US5010092A (en) * | 1989-12-22 | 1991-04-23 | Wisconsin Alumni Research Foundation | Protection against chemically-induced kidney damage by methimazole |
| JPH05255130A (ja) * | 1992-03-16 | 1993-10-05 | Asai Gerumaniumu Kenkyusho:Kk | メイラード反応抑制改善剤 |
| AU3955297A (en) * | 1997-03-11 | 1998-09-29 | Kuzmin, Konstantin Kuzmich | Process for increasing the therapeutic effect and reducing the toxicity of drugs, metals, and organic and inorganic compounds |
| DE19750287A1 (de) * | 1997-11-13 | 1998-04-02 | Heinz Kiefer | Homöopathisches Arzneimittel zur Entgiftung des Körpers von Quecksilber aus Amalgam-Zahnfüllungen |
| EP1105117A1 (en) * | 1998-08-17 | 2001-06-13 | Evgeny Vladimirovich Soloviev | Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1793288B1 (de) * | 1968-03-29 | 1971-05-27 | Daiichi Yakuhin Sangyo Kk | Verfahren zur Herstellung von Organogermaniumoxiden |
| GB1365997A (en) * | 1972-05-25 | 1974-09-04 | Asai K | Medicament comprising an organo germanium sesquioxide compound |
| US4271084A (en) * | 1978-03-01 | 1981-06-02 | Ryuichi Sato | Germanium-containing organic polymer and the process for the production of the same |
| JPS55122717A (en) * | 1979-03-15 | 1980-09-20 | Asai Gerumaniumu Kenkyusho:Kk | Interferon inducer |
| FR2548187B1 (fr) * | 1983-07-01 | 1988-07-15 | Asai Germanium Res Inst | Composes d'organo-germanium et leurs utilisations therapeutiques en tant qu'inhibiteurs des enzymes qui degradent les peptides opioides |
| JPS6016924A (ja) * | 1983-07-11 | 1985-01-28 | Asai Gerumaniumu Kenkyusho:Kk | 抗腫瘍剤 |
| JPS63107920A (ja) * | 1986-06-18 | 1988-05-12 | Asai Gerumaniumu Kenkyusho:Kk | 骨芽細胞活性化剤 |
-
1987
- 1987-10-29 JP JP62273746A patent/JP2698870B2/ja not_active Expired - Fee Related
-
1988
- 1988-10-20 CA CA000580729A patent/CA1314211C/en not_active Expired - Lifetime
- 1988-10-24 US US07/261,406 patent/US4919917A/en not_active Expired - Lifetime
- 1988-10-27 DE DE3836652A patent/DE3836652A1/de active Granted
- 1988-10-27 FR FR888814058A patent/FR2622446B1/fr not_active Expired - Fee Related
- 1988-10-27 GB GB8825170A patent/GB2211410B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4919917A (en) | 1990-04-24 |
| DE3836652C2 (enExample) | 1991-08-22 |
| DE3836652A1 (de) | 1989-05-11 |
| JPH01117834A (ja) | 1989-05-10 |
| JP2698870B2 (ja) | 1998-01-19 |
| FR2622446A1 (fr) | 1989-05-05 |
| GB2211410B (en) | 1991-06-12 |
| GB2211410A (en) | 1989-07-05 |
| GB8825170D0 (en) | 1988-11-30 |
| FR2622446B1 (fr) | 1994-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1314211C (en) | Agent for reducing nephrotoxicity caused by cyclosporin administration | |
| Shinobu et al. | Sodium N‐methyl‐D‐glucamine dithiocarbamate and cadmium intoxication | |
| Bernet et al. | 1H‐NMR Analysis of Intra‐and Intermolecular H‐Bonds of Alcohols in DMSO: Chemical Shift of Hydroxy Groups and Aspects of Conformational Analysis of Selected Monosaccharides, Inositols, and Ginkgolides | |
| EP1915994B1 (en) | Cyclic amine derivatives in combination with ppar regulators | |
| MX2008010772A (es) | Compuestos basados en imidazol, composiciones que los comprenden y metodos de su uso. | |
| EP1170288A3 (fr) | Dérivés de diphenylurée et leur utilisation en tant qu'antagonistes alpha2/5-HT2c | |
| Hobby et al. | Antimicrobial Action of Terramycin in Vitro and in Vivo. | |
| KR0163758B1 (ko) | 이소티오시아네이토 작용화된 금속 착화합물의 제조방법 | |
| WO1997045417A1 (en) | Cytokine production inhibitors, formulations thereof and their use in medicine, and methods for their identification | |
| Ghanayem et al. | Structure-activity relationships for the in vitro hematotoxicity of N-alkoxyacetic acids, the toxic metabolites of glycol ethers | |
| AU2001276677B2 (en) | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | |
| Yih et al. | Ks values of some homologous series of barbiturates and the relationship with the lipophilicity and metabolic clearance | |
| Tronchet et al. | α-Deoxy-α-hydroxyamino sugar phosphonates and the corresponding nitroxide free-radicals | |
| Dimmock et al. | Evaluation of some thiosemicarbazones of arylidene ketones and analogues for anticonvulsant activities | |
| CA2379974A1 (en) | Preparation of compounds useful for the detection of hypoxia | |
| CA2091651C (en) | Agent for suppresion and interception of mailard reaction | |
| US4859767A (en) | Glucosylmoranoline derivatives and use thereof for inhibiting increase in blood sugar levels | |
| JPH01117801A (ja) | 分離臓器洗浄保存液 | |
| CA1314210C (en) | Agent for improving reduced functions of organs caused by inhibited blood circulation | |
| CA1237667A (en) | Antitumor agent and method for treating tumor using the same | |
| SU895290A3 (ru) | Способ получени N-2-(6-оксибензтиазолил)-N'-фенилмочевин | |
| Perez et al. | Kinetics of the gas‐phase thermal elimination of N‐alkyl‐pyrazoles | |
| Lamchen et al. | Nitrones. Part X tautomerism in cyclic nitrones | |
| RU2841339C1 (ru) | 2-(4-Карбонилбензилидено)диптерокарпол, проявляющий гипогликемическую активность, его применение и способ его получения | |
| Vree et al. | Pharmacokinetics, acetylation‐deacetylation, renal clearance, and protein binding of sulphamerazine, N4‐acetylsulphamerazine, and N4‐trideuteroacetylsulphamerazine in ‘fast’and ‘slow’acetylators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |